지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2011.1
- 수록면
- 539 - 549 (11page)
이용수
초록· 키워드
오류제보하기
To date, more than 30 antibodies have been approved worldwide for therapeutic use. While the monoclonal antibody market is rapidly growing, the clinical use of therapeutic antibodies is mostly limited to treatment of cancers and immunological disorders. Moreover, antibodies against only five targets (TNF-α, HER2, CD20,EGFR, and VEGF) account for more than 80 percent of the worldwide market of therapeutic antibodies. The shortage of novel, clinically proven targets has resulted in the development of many distinct therapeutic antibodies against a small number of proven targets,based on the premise that different antibody molecules against the same target antigen have distinct biological and clinical effects from one another. For example,four antibodies against TNF-α have been approved by the FDA -- infliximab, adalimumab, golimumab, and certolizumab pegol -- with many more in clinical and preclinical development. The situation is similar for HER2, CD20, EGFR, and VEGF, each having one or more approved antibodies and many more under development. This review discusses the different binding characteristics, mechanisms of action, and biological and clinical activities of multiple monoclonal antibodies against TNF-α, HER-2, CD20, and EGFR and provides insights into the development of therapeutic antibodies.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Abbott / / Humira full prescribing information
Agus DB / 2002 / Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth / Cancer Cell 2 : 127 ~ 137
Alonso-Ruiz A / 2008 / Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety / BMC Musculoskelet Disord 9 : 52
Arnould L / 2006 / Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism / Br J Cancer 94 : 259 ~ 267
Barok M / 2007 / Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic dr
Agus DB / 2002 / Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth / Cancer Cell 2 : 127 ~ 137
Alonso-Ruiz A / 2008 / Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety / BMC Musculoskelet Disord 9 : 52
Arnould L / 2006 / Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism / Br J Cancer 94 : 259 ~ 267
Barok M / 2007 / Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic dr
이 논문의 저자 정보
최근 본 자료
댓글(0)
0